MedTrace Logo

A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps

NCT05865496 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2024-01-12

No results posted yet for this study

Summary

This study will evaluate the effect and safety of 611 in patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).

Conditions

  • Sinusitis
  • Nasal Polyps
  • Polyps

Interventions

DRUG

611

611 subcutaneous (SC) injection.

DRUG

Placebo

Placebo subcutaneous (SC) injection.

Sponsors & Collaborators

  • Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Qinghong Zhou, BS · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

  • Luo Zhang, MD · Beijing Tongren Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-30
Primary Completion
2024-05-31
Completion
2024-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05865496 on ClinicalTrials.gov